NO hope for patients with atrial fibrillation.
Rubart
Michael
M
Zipes
Douglas P
DP
D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000503:physiopathology*; D004195:Disease Models, Animal; D018450:Disease Progression; D004699:Endocardium / Q000378:metabolism; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D013552:Swine; D013923:Thromboembolism / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D013997:Time Factors
D000925:Anticoagulants; D017395:Plasminogen Activator Inhibitor 1; D009569:Nitric Oxide; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III